Skip to content

MBX Biosciences, Inc. MBX Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax

Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax at other companies

BankUnited logo
BankUnitedBKU
$2.52M+312%
Jackson Financial logo
Jackson FinancialJXN
-$333M-1.8%
BankUnited logo
BankUnitedBKU
$3.4M+312%
NMI Holdings Inc. logo
NMI Holdings Inc.NMIH
-$338K-1,879%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$13.5K-8.5%
Stewart Information Services logo
Stewart Information ServicesSTC
-$9K+75.0%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax.

The official record: MBX Biosciences, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s other comprehensive income (loss), reclassification adjustment from aoci for sale of securities, net of tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s other comprehensive income (loss), reclassification adjustment from AOCI for sale of securities, net of tax?
MBX Biosciences, Inc. (MBX) reported other comprehensive income (loss), reclassification adjustment from AOCI for sale of securities, net of tax of $13.5K in Q4 2025.
How has MBX Biosciences, Inc.'s other comprehensive income (loss), reclassification adjustment from AOCI for sale of securities, net of tax changed year-over-year?
MBX Biosciences, Inc.'s other comprehensive income (loss), reclassification adjustment from AOCI for sale of securities, net of tax decreased by 8.5% year-over-year, from $14.75K to $13.5K.
What is the long-term trend for MBX Biosciences, Inc.'s other comprehensive income (loss), reclassification adjustment from AOCI for sale of securities, net of tax?
Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s other comprehensive income (loss), reclassification adjustment from AOCI for sale of securities, net of tax has grown at a 324.3% compound annual growth rate (CAGR), from $3K to $54K.
What does other comprehensive income (loss), reclassification adjustment from AOCI for sale of securities, net of tax mean?
This metric tracks the reclassification of previously recognized unrealized gains or losses from accumulated other comprehensive income into the income statement upon the actual sale of securities. It serves to prevent double-counting of gains or losses when an investment is liquidated. This adjustment is critical for reconciling comprehensive income with net income and understanding the timing of realized investment performance.